Company: IMNN
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001641172-25-009572
Chunk: 102

Company: Imunon, Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 8
Chunk 102
---
 
  
    Less imputed interest 
     (140,366)
  
    Total lease liabilities 
    $1,008,048 

    Weighted average remaining life 
     2.59 

    Weighted average discount rate 
     9.98%

For the three-month period ended March 31, 2025, operating
lease expense was $165,232 and cash paid for operating leases included in operating cash flows was $165,231. For the three-month period
ended March 31, 2024, operating lease expense was $154,514 and cash paid for operating leases included in operating cash flows was $162,545.

Note 11. Commitments and Contingencies 

We are not currently a party to any material legal
proceedings.

Note 12. Subsequent Events 

The Company has evaluated its subsequent events from
March 31, 2025, through the date these consolidated financial statements were issued.

13

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following discussion and analysis of our financial
condition and results of operations This discussion contains forward-looking statements that involve risks and uncertainties. Our actual
results may differ materially from those discussed in forward-looking statements. Factors that might cause a difference include, but are
not limited to, those discussed above under “Cautionary Note Regarding Forward-Looking Statements,” and in Item 1A. Risk factors
in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

Overview

Imunon is a clinical-stage biotechnology company focused
on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms with the aim to generate safe, effective
and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. Imunon
is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the coding of proteins
and cytokines in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®,
is developed for the coding of viral antigens that can elicit a strong immunological response. This technology may represent a promising
platform for the development of vaccines in infectious diseases.

The Company’s lead clinical program, IMNN-001,
is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer